Cargando…
Targeting Natural Killer T Cells in Solid Malignancies
Natural killer T (NKT) cells are a unique subset of lymphocytes that recognize lipid antigens in the context of the non-classical class I MHC molecule, CD1d, and serve as a link between the innate and adaptive immune system through their expeditious release of cytokines. Whereas NKT have well-establ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227159/ https://www.ncbi.nlm.nih.gov/pubmed/34072042 http://dx.doi.org/10.3390/cells10061329 |
_version_ | 1783712459112054784 |
---|---|
author | Ingram, Zewde Madan, Shriya Merchant, Jenoy Carter, Zakiya Gordon, Zen Carey, Gregory Webb, Tonya J. |
author_facet | Ingram, Zewde Madan, Shriya Merchant, Jenoy Carter, Zakiya Gordon, Zen Carey, Gregory Webb, Tonya J. |
author_sort | Ingram, Zewde |
collection | PubMed |
description | Natural killer T (NKT) cells are a unique subset of lymphocytes that recognize lipid antigens in the context of the non-classical class I MHC molecule, CD1d, and serve as a link between the innate and adaptive immune system through their expeditious release of cytokines. Whereas NKT have well-established roles in mitigating a number of human diseases, herein, we focus on their role in cancer. NKT cells have been shown to directly and indirectly mediate anti-tumor immunity and manipulating their effector functions can have therapeutic significances in treatment of cancer. In this review, we highlight several therapeutic strategies that have been used to harness the effector functions of NKT cells to target different types of solid tumors. We also discuss several barriers to the successful utilization of NKT cells and summarize effective strategies being developed to harness the unique strengths of this potent population of T cells. Collectively, studies investigating the therapeutic potential of NKT cells serve not only to advance our understanding of this powerful immune cell subset, but also pave the way for future treatments focused on the modulation of NKT cell responses to enhance cancer immunotherapy. |
format | Online Article Text |
id | pubmed-8227159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82271592021-06-26 Targeting Natural Killer T Cells in Solid Malignancies Ingram, Zewde Madan, Shriya Merchant, Jenoy Carter, Zakiya Gordon, Zen Carey, Gregory Webb, Tonya J. Cells Review Natural killer T (NKT) cells are a unique subset of lymphocytes that recognize lipid antigens in the context of the non-classical class I MHC molecule, CD1d, and serve as a link between the innate and adaptive immune system through their expeditious release of cytokines. Whereas NKT have well-established roles in mitigating a number of human diseases, herein, we focus on their role in cancer. NKT cells have been shown to directly and indirectly mediate anti-tumor immunity and manipulating their effector functions can have therapeutic significances in treatment of cancer. In this review, we highlight several therapeutic strategies that have been used to harness the effector functions of NKT cells to target different types of solid tumors. We also discuss several barriers to the successful utilization of NKT cells and summarize effective strategies being developed to harness the unique strengths of this potent population of T cells. Collectively, studies investigating the therapeutic potential of NKT cells serve not only to advance our understanding of this powerful immune cell subset, but also pave the way for future treatments focused on the modulation of NKT cell responses to enhance cancer immunotherapy. MDPI 2021-05-27 /pmc/articles/PMC8227159/ /pubmed/34072042 http://dx.doi.org/10.3390/cells10061329 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ingram, Zewde Madan, Shriya Merchant, Jenoy Carter, Zakiya Gordon, Zen Carey, Gregory Webb, Tonya J. Targeting Natural Killer T Cells in Solid Malignancies |
title | Targeting Natural Killer T Cells in Solid Malignancies |
title_full | Targeting Natural Killer T Cells in Solid Malignancies |
title_fullStr | Targeting Natural Killer T Cells in Solid Malignancies |
title_full_unstemmed | Targeting Natural Killer T Cells in Solid Malignancies |
title_short | Targeting Natural Killer T Cells in Solid Malignancies |
title_sort | targeting natural killer t cells in solid malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227159/ https://www.ncbi.nlm.nih.gov/pubmed/34072042 http://dx.doi.org/10.3390/cells10061329 |
work_keys_str_mv | AT ingramzewde targetingnaturalkillertcellsinsolidmalignancies AT madanshriya targetingnaturalkillertcellsinsolidmalignancies AT merchantjenoy targetingnaturalkillertcellsinsolidmalignancies AT carterzakiya targetingnaturalkillertcellsinsolidmalignancies AT gordonzen targetingnaturalkillertcellsinsolidmalignancies AT careygregory targetingnaturalkillertcellsinsolidmalignancies AT webbtonyaj targetingnaturalkillertcellsinsolidmalignancies |